4-Chlorobenzo[b]thiophene CAS 66490-33-3 Purity >98.0% (GC) Brexpiprazole Intermedia Factory

Description:

Nomen chemicum: 4-Chlorobenzo[b]thiophene

CAS: 66490-33-3

Puritas: >98.0% (GC)

Aspectus: Colorless Liquid

Medium Brexpiprazole (CAS: 913611-97-9)

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Ruifu Chemical Supple Brexpiprazole Intermedia
Brexpiprazole CAS 913611-97-9
7-Hydroxyquinolinone CAS 70500-72-0
4-Bromobenzo[b]thiophene CAS 5118-13-8
1-(1-Benzothiophen-4-yl) piperazinum Hydrochloridum CAS 913614-18-3
7-(4-Chlorobutoxy) quinolin-2(1H)-one CAS 913613-82-8
4-Chlorobenzo[b]thiophene CAS 66490-33-3

Chemical Properties:

Nomen chemicum	4-Chlorobenzo[b]thiophene
Synonyma	4-Chloro-Benzo[b]thiophene;4-Chloro-1-Benzothiophene;4-Chlorobenzothiophene
CAS Number	66490-33-3
CATTUS Number	RF-PI1983
Stock Status	In Stock, Productio Ascendite ad Tons
Formulae hypotheticae	C8H5ClS
M. Pondus	168.64
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	Hyalina Liquid
Puritas / Analysis Methodus	>98.0% (GC)
Totalis immunditias	<2.00%
Infrared Imaginis	Conformat ut Structure
NMR	Conformat ut Structure
Test Standard	Enterprise Standard
Consuetudinem	Medium Brexpiprazole (CAS: 913611-97-9)

Sarcina & Repono:

sarcina: Fluorinated Utrem, 25kg/Drum, vel secundum exigentiam mos

Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine et humore

commoda:

FAQ:

Applicatio:

4-Chlorobenzo[b]thiophene (CAS: 66490-33-3) medius est Brexpiprazolis (CAS: 913611-97-9).Brexpiprazole novum medicamentum antipsychoticum est, quod actio- nem serotonin dopamine modulantis inservit et efficaciam adiunctivam tractandi in aegris cum inordinatione depressiva maiore ostendit (MDD).Medicamentum exhibet singularem profanum pharmacologicum, agonista serotonin 5-HT1A et dopamine receptorum 5-HT1A et tamquam plenus adversariorum receptorum 5-HT2A et noradrenalini α1B/2C, cum simili ligatura affinitatis subnanomolaris.Medicamentum, quod ab Otsuka et Lundbeck evolvit, anno 2015 ab FDA probatum est ad schizophreniae curationem et adiunctivam curationem pro tristitia.Brexpiprazole late censetur successor Otsuka medicamento aripiprazoli antipsychotici (nomen artis Abilify) cuius patentes mense Augusto 2014 elapsi sunt.